These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37188913)

  • 1. Accurate prognosis for localized prostate cancer through coherent voting networks with multi-omic and clinical data.
    Pellegrini M
    Sci Rep; 2023 May; 13(1):7875. PubMed ID: 37188913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer.
    Kiebish MA; Cullen J; Mishra P; Ali A; Milliman E; Rodrigues LO; Chen EY; Tolstikov V; Zhang L; Panagopoulos K; Shah P; Chen Y; Petrovics G; Rosner IL; Sesterhenn IA; McLeod DG; Granger E; Sarangarajan R; Akmaev V; Srinivasan A; Srivastava S; Narain NR; Dobi A
    J Transl Med; 2020 Jan; 18(1):10. PubMed ID: 31910880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
    Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
    Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
    Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
    Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended application of genomic selection to screen multiomics data for prognostic signatures of prostate cancer.
    Li R; Wang S; Cui Y; Qu H; Chater JM; Zhang L; Wei J; Wang M; Xu Y; Yu L; Lu J; Feng Y; Zhou R; Huang Y; Ma R; Zhu J; Zhong W; Jia Z
    Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32898860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
    Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R
    Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local augmented graph neural network for multi-omics cancer prognosis prediction and analysis.
    Zhang Y; Xiong S; Wang Z; Liu Y; Luo H; Li B; Zou Q
    Methods; 2023 May; 213():1-9. PubMed ID: 36933628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
    Kohaar I; Petrovics G; Srivastava S
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer.
    Murphy K; Murphy BT; Boyce S; Flynn L; Gilgunn S; O'Rourke CJ; Rooney C; Stöckmann H; Walsh AL; Finn S; O'Kennedy RJ; O'Leary J; Pennington SR; Perry AS; Rudd PM; Saldova R; Sheils O; Shields DC; Watson RW
    Mol Oncol; 2018 Sep; 12(9):1513-1525. PubMed ID: 29927052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker Identification through Multiomics Data Analysis of Prostate Cancer Prognostication Using a Deep Learning Model and Similarity Network Fusion.
    Wang TH; Lee CY; Lee TY; Huang HD; Hsu JB; Chang TH
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34064004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
    Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
    PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-omics: A Self-supervised Learning Framework for Multi-omics Cancer Data.
    Hashim S; Nandakumar K; Yaqub M
    Pac Symp Biocomput; 2023; 28():263-274. PubMed ID: 36540983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
    Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are localized prostate cancer biomarkers useful in the clinical practice?
    Carneiro A; Priante Kayano P; Gomes Barbosa ÁR; Langer Wroclawski M; Ko Chen C; Cavlini GC; Reche GJ; Sanchez-Salas R; Tobias-Machado M; Sowalsky AG; Bianco B
    Tumour Biol; 2018 Sep; 40(9):1010428318799255. PubMed ID: 30204063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and Emerging Diagnostic and Prognostic Immunohistochemical Biomarkers in Prostate Pathology.
    Giannico GA; Arnold SA; Gellert LL; Hameed O
    Adv Anat Pathol; 2017 Jan; 24(1):35-44. PubMed ID: 27941540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
    Lieberman R
    Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy.
    Casanova-Salas I; Rubio-Briones J; Calatrava A; Mancarella C; Masiá E; Casanova J; Fernández-Serra A; Rubio L; Ramírez-Backhaus M; Armiñán A; Domínguez-Escrig J; Martínez F; García-Casado Z; Scotlandi K; Vicent MJ; López-Guerrero JA
    J Urol; 2014 Jul; 192(1):252-9. PubMed ID: 24518785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.